Pediatric toxic epidermal necrolysis treated successfully with infliximab

Successful management of toxic epidermal necrolysis ( TEN ) with tumor necrosis factor‐α inhibitors has been described in adults. We present a case of a 7‐year‐old boy with infection‐associated TEN , diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae . Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Sequelae were mild, consisting of postinflammatory hyperpigmentation and dry eyes.